Overview

Study of DA-9801 to Treat Diabetic Neuropathy

Status:
Completed

Trial end date:
2015-01-01

Target enrollment:

Participant gender:

Summary

To evaluate the effectiveness of DA-9801 at 300mg, 600mg, 900mg and placebo, in reducing pain in subjects with diabetic neuropathic pain compared to their baseline values.

Phase:

Phase 2

Details

Lead Sponsor:

Dong-A ST Co., Ltd.
NeuroBo Pharmaceuticals Inc.

Collaborator:

Dong-A ST Co., Ltd.